Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc has completed its previously announced acquisition of RAPT Therapeutics, valuing RAPT at an approximate aggregate equity value of $2.2 billion, with GSK’s upfront cash investment around $1.9 billion net of cash acquired.
The deal gives GSK global rights to the food-allergy candidate ozureprubart, excluding mainland China, Macau, Taiwan and Hong Kong. Ozureprubart is a long-acting anti-IgE monoclonal antibody in phase IIb development, aiming for 12‑week dosing versus current 2–4 week injections and potentially serving patients currently ineligible for existing anti‑IgE therapy.
Phase IIb monotherapy data from the prestIgE trial are expected in 2027, with phase III studies planned in at‑risk adult and paediatric populations. GSK will also assume success‑based milestone and royalty obligations for ozureprubart owed to Shanghai Jeyou Pharmaceutical.
GSK plc reports that on 2 March 2026 it repurchased 500,000 ordinary shares of 31¼ pence each through BNP Paribas, at a volume‑weighted average price of 2,180.14p, with prices ranging between 2,168.00p and 2,195.00p per share.
The shares will be held as treasury stock under GSK’s existing buyback programme. Since 17 February 2026, GSK has bought 4,636,000 ordinary shares. After this purchase, it holds 244,527,094 shares in treasury and has 4,071,635,394 voting shares in issue, with treasury shares representing 6.01% of voting rights.
GSK plc reports that, acting through BNP Paribas, it repurchased 430,000 ordinary shares on 27 February 2026 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 2,153.00p and 2,197.00p per share, at a volume‑weighted average price of 2,179.36p.
The purchased shares will be held as treasury shares. Since 17 February 2026, the company has bought back a total of 4,136,000 ordinary shares. Following this latest transaction, GSK holds 244,027,094 shares in treasury and has 4,072,135,394 ordinary shares in issue, which is also the total number of voting rights. Treasury shares now represent 5.99% of voting rights.
GSK plc reports its share capital and voting rights position as of 28 February 2026. The company had 4,316,162,488 issued ordinary shares of 31 ¼ pence each, with 244,027,094 of these held in treasury. Shares held in treasury do not carry voting rights.
After excluding treasury shares, the total number of voting rights in GSK is 4,072,135,394. Shareholders can use this figure as the denominator when calculating whether they must notify the company and the UK regulator of any interests or changes in their holdings.
GSK plc reports that executive Maya Martinez-Davis acquired 70.566 American Depositary Shares at $59.5200 each on 2026-02-20 through dividend reinvestment in her GSK Executive Supplemental Savings Plan account. The transaction took place on the New York Stock Exchange and was disclosed as an initial notification.
GSK plc reports that, on 26 February 2026, it bought 545,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme, at a volume‑weighted average price of 2,186.88p per share.
The shares will be held as treasury shares. After this transaction, GSK holds 243,597,094 shares in treasury and has 4,072,555,332 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 5.98% of voting rights.
GSK reports that China’s National Medical Products Administration has accepted its new drug application for linerixibat for priority review to treat cholestatic pruritus in adults with primary biliary cholangitis, a rare autoimmune liver disease.
The submission is based on the positive phase III GLISTEN trial, where linerixibat showed rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo, with a safety profile consistent with earlier studies and its IBAT-inhibitor mechanism. In China, primary biliary cholangitis affects about 280,000 people, and cholestatic pruritus can impact up to 89% of patients over the course of their disease, with few effective treatment options. Linerixibat has Orphan Drug Designation in the US, EU and Japan, and marketing applications are under review in the US, EU, UK and Canada, but it is not yet approved anywhere.
GSK reports that Japan's Ministry of Health, Labour and Welfare has accepted for review a new drug application for bepirovirsen as a treatment for adults with chronic hepatitis B. This is the first regulatory filing globally for the drug and follows positive phase III B-Well trial results showing statistically significant and clinically meaningful functional cure rates when added to standard therapy.
Bepirovirsen, an investigational antisense oligonucleotide, targets hepatitis B viral RNA to reduce viral replication and surface antigen levels, while stimulating the immune system. It has SENKU designation in Japan, which enables expedited review, and has also received Fast Track or similar designations in other major markets, but it is not yet approved anywhere.
GSK plc reports that on 25 February 2026 it repurchased 455,000 ordinary shares of 31¼ pence each through BNP Paribas at a volume-weighted average price of 2,209.58p, with prices ranging from 2,176.00p to 2,217.00p per share.
The shares will be held as treasury shares as part of its existing buyback programme started under a non-discretionary agreement on 17 February 2026, since when 3,161,000 shares have been bought. After this transaction, GSK holds 243,052,094 shares in treasury and has 4,073,100,332 shares in issue and voting rights, with treasury shares representing 5.97% of voting rights.
GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares through a company pension plan. The transaction involved the purchase of 11.163 ADS at a price of CAD 82.8205 per ADS on 2026-02-13 on the New York Stock Exchange.